Autolus Therapeutics plc American Depositary Share (AUTL)

FairStock Score: 45/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings and a margin of safety, and Autolus does not yet qualify. It is a biotechnology company with a commercial cell therapy, AUCATZYL, and a pipeline candidate, obe-cel. Revenue is scaling: filed fiscal 2023 revenue was $1.7M, fiscal 2024 was $10.1M, and fiscal 2025 was $75.4M. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $45.7M and net loss was $39.1M, versus revenue of $20.9M and net loss of $47.9M in fiscal Q2 2025. That top-line progress is real, but the bottom line remains deeply negative. Fiscal 2025 net loss was $287.5M, worse than fiscal 2024's $220.7M, and the company has lost money in each of the last four years, which is why the computed Lynch category is none. At the 2026-10-13 close of $1.62, FairStock's calculations show a P/B of 0.27, P/E of -1.53, ROE of -133%, ROCE of -25.44%, and FCF yield of -55.9%. The low P/B might tempt a Graham-style investor, but book value is being consumed by cash burn; trailing free cash flow is -$240.8M. Debt-to-equity is 4.91, Altman Z is -3.18, and Piotroski is 5/9. The balance sheet looks stressed, and the company depends on capital markets. This is a speculative growth story, not a proven compounding machine. The moat is unproven. I would need evidence of sustained revenue, narrowing losses, and self-funding before calling it a value investment.

In plain English: Autolus Therapeutics is a biotechnology company that develops and sells cell therapies for cancer and autoimmune diseases. Revenue is growing quickly, but the company is still losing large amounts of money, carries high debt, and burns cash. At $1.62, the stock looks inexpensive compared with its accounting book value, but because profits are negative, it is a speculative situation rather than an obvious bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer